Tower Research Capital LLC (TRC) - INOVIO PHARMACEUTICALS INC ownership

INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 1 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of INOVIO PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$14,300
-14.3%
36,760
-1.5%
0.00%
-100.0%
Q2 2023$16,680
+30227.3%
37,316
-44.4%
0.00%
-50.0%
Q1 2023$55
+57.1%
67,084
+198.7%
0.00%
+100.0%
Q4 2022$35
-100.0%
22,455
-82.6%
0.00%
-75.0%
Q3 2022$222,000
+101.8%
129,084
+101.8%
0.00%
+100.0%
Q2 2022$110,000
-33.3%
63,972
+39.6%
0.00%0.0%
Q1 2022$165,000
-60.1%
45,832
-44.8%
0.00%
-71.4%
Q4 2021$414,000
-4.8%
83,059
+36.7%
0.01%
-36.4%
Q3 2021$435,000
+405.8%
60,758
+554.6%
0.01%
+450.0%
Q2 2021$86,000
-45.2%
9,281
-45.1%
0.00%
-33.3%
Q1 2021$157,000
+214.0%
16,913
+201.5%
0.00%
+50.0%
Q4 2020$50,000
-90.8%
5,609
-88.1%
0.00%
-66.7%
Q3 2020$545,000
-9.9%
46,976
+109.2%
0.01%
-76.0%
Q2 2020$605,000
+7462.5%
22,452
+474.4%
0.02%
+2400.0%
Q3 2019$8,000
+33.3%
3,909
+97.2%
0.00%
Q2 2019$6,000
+200.0%
1,982
+252.0%
0.00%
Q4 2018$2,000
-96.9%
563
-95.9%
0.00%
-100.0%
Q1 2018$65,000
+983.3%
13,808
+922.8%
0.01%
+500.0%
Q4 2017$6,000
-87.8%
1,350
-82.7%
0.00%
-75.0%
Q3 2017$49,000
+81.5%
7,786
+99.0%
0.00%
+33.3%
Q4 2016$27,000
+440.0%
3,912
+682.4%
0.00%
Q3 2016$5,000
-58.3%
500
-61.0%
0.00%
-100.0%
Q2 2016$12,000
+500.0%
1,283
+608.8%
0.00%
Q1 2016$2,000
-89.5%
181
-93.5%
0.00%
-100.0%
Q4 2015$19,000
-94.3%
2,803
-95.2%
0.00%
-90.9%
Q3 2015$335,000
+805.4%
57,914
+1178.5%
0.03%
+1000.0%
Q2 2015$37,000
-57.0%
4,530
-57.1%
0.00%
-72.7%
Q1 2015$86,000
+8500.0%
10,571
+8935.0%
0.01%
Q3 2014$1,000
-98.2%
117
-97.7%
0.00%
-100.0%
Q2 2014$55,0005,1170.01%
Other shareholders
INOVIO PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Round Table Services, LLC 129,500$1,207,0000.72%
STONERIDGE INVESTMENT PARTNERS LLC 252,376$2,352,0000.34%
Bellevue Group AG 155,000$1,445,0000.26%
WASATCH ADVISORS LP 1,861,553$17,350,0000.26%
Blue Clay Capital Management, LLC 13,000$121,0000.14%
Virtus ETF Advisers LLC 24,058$224,0000.11%
EMERALD ADVISERS, LLC 203,737$1,899,0000.08%
Vident Investment Advisory, LLC 63,383$591,0000.08%
Thomas J. Herzfeld Advisors, Inc. 15,000$140,0000.08%
GSA CAPITAL PARTNERS LLP 94,400$880,0000.05%
View complete list of INOVIO PHARMACEUTICALS INC shareholders